The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Arog
A phase I/Ib study of crenolanib with ramucirumab (RAM)/paclitaxel (PTX) as second-line therapy (2L tx) for advanced esophagogastric adenocarcinoma (EGA).
 
Megan Greally
No Relationships to Disclose
 
Sujata Jha
No Relationships to Disclose
 
Sam S. Yoon
No Relationships to Disclose
 
Jia Li
No Relationships to Disclose
 
Avni Mukund Desai
No Relationships to Disclose
 
Elizabeth Won
No Relationships to Disclose
 
David Paul Kelsen
No Relationships to Disclose
 
David H. Ilson
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech
 
Yelena Yuriy Janjigian
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck; Merck Serono; Pfizer
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Genentech; Lilly; Roche
 
Kathrena Aljallad
No Relationships to Disclose
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Merck Sharp & Dohme
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme